View source for 18271588. HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION simplified abstract (The Regents of the University of California)

=HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION=


==Organization Name==

[[:Category:The Regents of the University of California|The Regents of the University of California]]


[[Category:The Regents of the University of California]]

==Inventor(s)==

[[:Category:Gregory Ku of San Francisco CA (US)|Gregory Ku of San Francisco CA (US)]][[Category:Gregory Ku of San Francisco CA (US)]]

==HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18271588 titled 'HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION

==Simplified Explanation==

The abstract describes methods for treating diabetes by administering a serotonin receptor 1F (HTR1F) antagonist to increase survival of pancreatic beta cells in conjunction with pancreatic islet transplantation. 

* HTR1F antagonist administration can increase survival of pancreatic beta cells
* Can be used in conjunction with pancreatic islet transplantation
* Examples of HTR1F antagonists include substituted piperidine, methysergide, and methiothepin

== Potential Applications ==
The technology could be applied in the treatment of diabetes patients by improving the survival of pancreatic beta cells and enhancing the effectiveness of pancreatic islet transplantation.

== Problems Solved ==
This technology addresses the issue of pancreatic beta cell survival in diabetes patients, which is crucial for maintaining proper insulin production and blood sugar regulation.

== Benefits ==
The benefits of this technology include potentially improving the outcomes of pancreatic islet transplantation and enhancing the overall management of diabetes in patients.

== Potential Commercial Applications ==
A potential commercial application of this technology could be the development of novel treatments for diabetes patients that target pancreatic beta cell survival and function.

== Possible Prior Art ==
One possible prior art could be research on the use of serotonin receptor antagonists in the treatment of diabetes or related conditions. 

=== Unanswered Questions ===

== How does the administration of HTR1F antagonists impact the survival of pancreatic beta cells in diabetes patients undergoing islet transplantation? ==
The article does not provide specific details on the mechanism by which HTR1F antagonists increase the survival of pancreatic beta cells in conjunction with pancreatic islet transplantation.

== Are there any potential side effects or limitations associated with the administration of HTR1F antagonists in diabetes patients? ==
The article does not address any potential side effects or limitations that may be associated with the use of HTR1F antagonists in diabetes patients, which could be important considerations for further research and development.


==Original Abstract Submitted==

Methods for treating diabetes are described. The methods include administration of a serotonin receptor 1F (HTR1F) antagonist, such as a substituted piperidine, methysergide, or methiothepin, to a subject in need thereof. Administration of the HTR1F antagonist can increase survival of pancreatic beta cells in conjunction with pancreatic islet transplantation. Methods for transplanting pancreatic islets to subjects such as diabetes patients are also described.



[[Category:A61K31/496]]
[[Category:A61K31/4709]]
[[Category:A61K31/48]]
[[Category:A61K31/7088]]
[[Category:A61P3/10]]